Global Biological Therapies for Cancer Market 2022
- Relatório de mercado
- EU IA: HB24675G
- Prazo de entrega: 1 Dia de negócios
- Marcação: Biological Therapies for Cancer
Descrição
A study by StrategyHelix indicates that the global biological therapies for cancer market is expected to increase by US$ 50.0 bilhão de 2022 para 2028, obtendo um CAGR de 8.2% durante o período de previsão.
O relatório fornece dados atualizados sobre o tamanho do mercado para o período 2018-2021 e previsão para 2028 covering key market aspects like sales value for biological therapies for cancer. The global biological therapies for cancer market is segmented on the basis of product, and region. Baseado no produto, the global biological therapies for cancer market is categorized into CAR T-cell therapies, monoclonal antibodies, vaccines. The monoclonal antibodies segment held the largest share of the global biological therapies for cancer market in 2021 and is anticipated to hold its share during the forecast period. In terms of geography, the global biological therapies for cancer market has been segmented into Asia Pacific, Europa, América do Norte, Rest of the World (RoW). Globally, North America made up the largest share of the biological therapies for cancer market.
The global biological therapies for cancer market is highly competitive. Some of the leading companies operating in the market are Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences Inc., GlaxoSmithKline plc (GSK), Janssen Pharmaceuticals Inc., Merck KGaA, Novartis International AG, Pfizer Inc.
O relatório é um recurso inestimável para empresas e organizações ativas neste setor. It provides a cohesive picture of the biological therapies for cancer market to help drive informed decision making for industry executives, decisores políticos, acadêmico, e analistas.
Escopo do relatório
produtos: CAR T-cell therapies, monoclonal antibodies, vaccines
Região: Ásia-Pacífico, Europa, América do Norte, Rest of the World (RoW)
Anos considerados: este relatório cobre o período 2018 para 2028
Principais benefícios para as partes interessadas
– Get a comprehensive picture of the global biological therapies for cancer market
– Identifique setores de crescimento e tendências para investimento
Índice
Papel 1. Introdução
– Escopo do estudo
– Período de estudos
– Escopo geográfico
– Metodologia de Pesquisa
Papel 2. Biological therapies for cancer market overview
Papel 3. Divisão de mercado por produto
– CAR T-cell therapies
– Monoclonal antibodies
– Vaccines
Papel 4. Market breakdown by region
– Ásia-Pacífico
– Europa
– América do Norte
– Rest of the World (RoW)
Papel 5. Principais empresas
– Amgen Inc.
– AstraZeneca plc
– Bristol-Myers Squibb Company (BMS)
– Eli Lilly and Company
– F. Hoffmann-La Roche AG
– Genmab A/S
– Gilead Sciences, Inc..
– GlaxoSmithKline plc (GSK)
– Janssen Pharmaceuticals, Inc..
– Merck KGaA
– Novartis International AG
– Pfizer Inc.
Sobre StrategyHelix
Isenção de responsabilidade
USD 650